KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Merck (MRK) Net Cash Flow (2016 - 2026)

Merck has reported Net Cash Flow over the past 18 years, most recently at -$9.3 billion for Q1 2026.

Quarterly Net Cash Flow fell 95.55% to -$9.3 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$3.7 billion through Mar 2026, down 221.63% year-over-year, with the annual reading at $809.0 million for FY2025, 87.93% down from the prior year.
Net Cash Flow was -$9.3 billion for Q1 2026 at Merck, down from -$3.6 billion in the prior quarter.
Over five years, Net Cash Flow peaked at $10.2 billion in Q3 2025 and troughed at -$9.3 billion in Q1 2026.
The 5-year median for Net Cash Flow is -$1.0 billion (2024), against an average of -$154.9 million.
Year-over-year, Net Cash Flow plummeted 712.35% in 2023 and then soared 245.29% in 2024.
A 5-year view of Net Cash Flow shows it stood at $1.1 billion in 2022, then crashed by 272.52% to -$1.9 billion in 2023, then soared by 48.46% to -$1.0 billion in 2024, then crashed by 258.23% to -$3.6 billion in 2025, then plummeted by 158.09% to -$9.3 billion in 2026.
Per Business Quant, the three most recent readings for MRK's Net Cash Flow are -$9.3 billion (Q1 2026), -$3.6 billion (Q4 2025), and $10.2 billion (Q3 2025).